Shimadzu partners with Abbott to integrate LC-MS automation with AlinIQ AMS lab informatics

Bitget2026/10/09 04:00

Shimadzu started development, validation of an LC-MS automation solution with Abbott’s AlinIQ AMS at St. Vincent’s Hospital, Melbourne. Integration targets streamlined core-lab workflows, faster turnaround, improved reliability for clinical testing. Project uses Shimadzu’s CLAM-2040 CL sample-prep module, LCMS-8060 CL mass spectrometer, reagent kits linked to AlinIQ AMS. Move aligns with its June 4, 2026 plan to expand clinical diagnostics as a core growth driver via global partnerships. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shimadzu Corporation published the original content used to generate this news brief on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

A certain exchange has approximately 5.492 million dollars worth of BTC spot sell orders listed at 83,836 dollars, about 0.40% away from the current price.

Chaincatcher•2026/10/12 04:07

Jefferies raises Tesla's target price to $400

格隆汇•2026/10/12 03:59

Goldman Sachs (GS.US) stock plunges 22% into bear market, financial report becomes the key to a breakthrough

Goldman Sachs' market value evaporated by several billions, with its share price down more than 22% from the year's high. Despite Q3 revenue exceeding expectations, a 41% drop in M&A activity and a slowdown in IPOs have dampened market sentiment. Analysts project a 12% revenue increase in Q4, but technical indicators suggest there is further downside risk to $783. Rumors about management transitions have also drawn attention.

智通财经•2026/10/12 03:52

Delivery soared by 85% but failed to prevent the death cross; Rivian (RIVN.US) dilution risk sparks panic

Despite the R2 model driving an 85% year-on-year increase in deliveries, Rivian's stock price continues to decline due to technical death cross, high short interest, and risks of equity dilution, facing a severe market test.

智通财经•2026/10/12 03:52